Tech Center 1600 • Art Units: 1633
This examiner grants 21% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18176871 | DESTABILIZED ARE 3'UTRs AS THERAPEUTICS FOR CANCER | Non-Final OA | President and Fellows of Harvard College |
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | Final Rejection | THE BROAD INSTITUTE, INC. |
| 18547809 | COMPOSITION AND METHODS FOR THE TREATMENT OF FABRY DISEASE | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18458139 | Skin Probiotics | Non-Final OA | The Regents of the University of California |
| 17925470 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 16623268 | MATERIALS AND METHODS FOR INCREASING IMMUNE RESPONSES | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18022415 | METHOD FOR IN VITRO PRODUCTION OF RED BLOOD CELLS | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18274133 | PHOTO-CROSSLINKED BIOREDUCIBLE POLYMERIC NANOPARTICLES FOR ENHANCED RNA DELIVERY | Non-Final OA | The Johns Hopkins University |
| 18298900 | RNA INTERFERENCE DELIVERY FORMULATION AND METHODS FOR MALIGNANT TUMORS | Final Rejection | Nitto Denko Corporation |
| 17925404 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | Non-Final OA | Generation Bio Co. |
| 15327794 | SUBSET-OPTIMIZED CHIMERIC ANTIGEN RECEPTOR-CONTAINING T-CELLS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18088544 | POLYMERIC NANOPARTICLES AND DERIVATIVES THEREOF FOR NUCLEIC ACID BINDING AND DELIVERY | Final Rejection | University of Massachusetts |
| 18307258 | METHOD OF TREATING BREAST CANCER IN A SUBJECT BY INHIBITING TUBB2B | Non-Final OA | City University of Hong Kong |
| 17918887 | ENHANCING AAV-MEDIATED DELIVERY AND TRANSDUCTION WITH POLYVINYL ALCOHOL | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17765507 | METHOD FOR PRODUCING HEPARIN-LIKE SUBSTANCE, RECOMBINANT CELL, AND METHOD FOR PRODUCING THE SAME | Final Rejection | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 16973603 | COMPOSITIONS AND METHODS FOR IN VIVO POST TRANSLATIONAL MODIFICATION | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 18433277 | METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | Non-Final OA | Seattle Children's Hospital, dba Seattle Children's Research Institute |
| 18431597 | Liver Specific Delivery of Messenger RNA | Final Rejection | Translate Bio, Inc. |
| 18334330 | LIVER SPECIFIC DELIVERY OF MESSENGER RNA | Final Rejection | Translate Bio, Inc. |
| 17605343 | THIOESTER CATIONIC LIPIDS | Non-Final OA | Translate Bio, Inc. |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Final Rejection | Translate Bio, Inc. |
| 17829271 | Low Molecular Weight Silk Compositions and Stabilizing Silk Compositions | Final Rejection | Trustees of Tufts College |
| 18310969 | COMPOSITION FOR PREVENTING OR TREATING PROGERIA AND NATURAL AGING THROUGH GENE EDITING | Final Rejection | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18540440 | ANTIBODY PRODUCTION | Non-Final OA | ROGER KINGDON CRAIG |
| 18246447 | NUCLEIC ACID NANOSTRUCTURES FOR DELIVERY OF NUCLEIC ACID SEQUENCES TO CELLS | Non-Final OA | UCL BUSINESS LTD |
| 18154229 | SUPRAMOLECULAR CELL-BASED CARRIER, DRUG LOADING SYSTEM AND ITS PREPARATION METHOD | Non-Final OA | University of Macau |
| 17054393 | METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS | Non-Final OA | Beam Therapeutics Inc. |
| 18172176 | PRODUCTION OF EXTRACELLULAR VESICLES IN SINGLE-CELL SUSPENSION USING CHEMICALLY-DEFINED CELL CULTURE MEDIA | Final Rejection | LONZA SALES AG |
| 18471761 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | Final Rejection | Board of Regents of The University of Texas System |
| 18466575 | MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS | Non-Final OA | Vertex Phamaceuticals Incorporated |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy